Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants treated with deucravacitinib | Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Deucravacitinib | Drug | As per product label |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score | Week 16 | |
| Participant psoriasis Body Surface Area (BSA) involvement | Week 16 | |
| Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3 | Week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response | Baseline and Weeks 4, 12, 24, 36, and 52 | |
| Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult participants aged ≥ 18 years who have been diagnosed with moderate plaque psoriasis who are starting deucravacitinib treatment in China
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution - 0001 | Guangzhou | Guangdong | 510091 | China | ||
| Local Institution - 0002 |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| FDA Safety Alerts and Recalls | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000628674 | deucravacitinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline and Weeks 4, 12, 24, 36, and 52 |
| Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline | Weeks 4, 12, 16, 24, 36, and 52 |
| Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3% | Baseline and Weeks 4, 12, 16, 24, 36, and 52 |
| Change in Body Surface Area (BSA) involvement from baseline to follow-up | Weeks 4, 12, 24, 36, and 52 |
| Static Physician's Global Assessment (sPGA) 0/1 response at follow-up | Weeks 4, 12, 24, 36, and 52 |
| Participants change in Static Physician's Global Assessment (sPGA) score from baseline | Baseline and Weeks 4, 12, 16, 24, 36, and 52 |
| Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score | Baseline and Weeks 4, 12, 16, 24, 36, and 52 |
| Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score | Baseline and Weeks 4, 12, 16, 24, 36, and 52 |
| Change in participant Dermatology Life Quality Index (DLQI) score from baseline | Baseline and Weeks 4, 12, 16, 24, 36, and 52 |
| Handan |
| Hebei |
| 056029 |
| China |
| Local Institution - 0005 | Dalian | Liaoning | 116021 | China |
| Local Institution - 0004 | Shanghai | Shanghai Municipality | 200080 | China |
| Local Institution - 0003 | Beijing | 102218 | China |